Certainty in Testing Times
Rapid, portable, and accurate diagnostics, where you need it.
ProtonDx is launching a series of cutting‑edge diagnostic tools founded on a decade of research and development at Imperial College London.
Our vision is to develop ultra‑rapid, extremely precise, molecular testing for everyone at the point‑of‑need.
Rapid, portable, and accurate diagnostics.
Dragonfly combines portability, speed, high sensitivity, high specificity, and convenience to differentiate and detect multiple pathogens from a single sample in less than 30 minutes.
High quality DNA and RNA samples are extracted from nasopharyngeal swabs and prepared for testing with minimal handling, providing results equivalent to the ‘gold standard’ polymerase chain reaction test (PCR) at point‑of‑need. In addition, the Dragonfly platform provides confidence that the patient sample has been taken and tested correctly.
Dragonfly test panels are available to detect a variety of pathogens.
The Dragonfly system is a CE‑marked in vitro diagnostic medical device and complies with the current European In‑vitro Diagnostic Devices Directive (IVDD 98/79/EC).
The latest news of Dragonfly being used at the Commonwealth Games 2022 can be found here.
Rapid identification of SARS‑CoV‑2 where you need it.
The Dragonfly SARS‑CoV‑2 test panel is designed to help combat the ongoing COVID‑19 pandemic. It has the potential to detect current and emerging variants with PCR equivalent accuracy in under 30 minutes. As a molecular test, Dragonfly is capable of detecting low viral loads associated with an early stage in the disease cycle.
The Dragonfly system for rapid identification of SARS‑CoV‑2 is CE‑marked and commercially available as an in vitro diagnostic tool in the European Union.
If it is not COVID‑19 what is it?
With many respiratory illnesses presenting similar symptoms, effective treatment is dependent on an accurate diagnosis. The Dragonfly respiratory test panel is designed to rapidly identify and distinguish Influenza A, Influenza B, Respiratory Syncytial Virus (RSV), and Rhinovirus as well as SARS‑CoV‑2.
The Dragonfly system for identification and differentiation of common respiratory pathogens is CE‑marked and commercially available as an in vitro diagnostic tool in the European Union.
The portability of Dragonfly allows teams to travel with an accurate testing system – even to remote locations. It enables timely treatment decision making which helps optimise performance, minimises unnecessary antibiotic use, and supports appropriate return to training.
The travel industry has specific needs which Dragonfly is particularly designed to meet. Crew members and passengers could potentially be tested prior to, or even at the point of embarkation with speed and certainty.
Residents of care homes are vulnerable as Flu and Covid-19 are devastating to these high-risk populations. Early identification enabling isolation and treatment can make a difference. The Dragonfly SARS-CoV-2 and respiratory panels can test visitors, staff and residents quickly, easily and reliably.
A single COVID-19 positive employee or visitor can close a business for days. Rapid on-site Dragonfly testing potentially provides greater productivity with the continuity of business.
Point-of-care diagnostics allow rapid triage with under 30 minute “sample-to-result” services, enhancing patient experience and hospital service offerings.
Sample-to-result in under 30 minutes supports local medical providers to make timely decisions on appropriate treatment for patients.
Dragonfly provides an opportunity for pharmacies to potentially offer faster, accurate, molecular tests on-site while a customer waits.
Dragonfly is ideally suited to low-resource environments, enabling testing in local clinics and remote locations.
Certainty in testing and confidence in our daily life.